Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL15153831 | 0.97 | NUDT1 (0.50) | NUDT1L3MBTL1DYRK1AADORA2AGRIN2D | |
| SCHEMBL16121286 | 0.75 | L3MBTL1 (0.39) | NUDT1L3MBTL1 | |
| SCHEMBL1797539 | 0.75 | NUDT1 (0.34) | NUDT1 | |
| SCHEMBL24387465 | 0.72 | L3MBTL1 (0.37) | NUDT1L3MBTL1 | |
| SCHEMBL24386932 | 0.72 | HTR2C (0.50) | NUDT1L3MBTL1 | |
| SCHEMBL2182683 | 0.72 | L3MBTL1 (0.44) | NUDT1L3MBTL1ADORA2A | |
| SCHEMBL1507164 | 0.72 | NUDT1 (0.45) | NUDT1L3MBTL1DYRK1A | |
| Bromide SCHEMBL17873904 | 0.71 | L3MBTL1 (0.40) | NUDT1L3MBTL1 | |
| SCHEMBL5775163 | 0.70 | NUDT1 (0.43) | NUDT1L3MBTL1DYRK1AADORA2AGRIN2D | |
| SCHEMBL27082496 | 0.70 | NUDT1 (0.43) | NUDT1L3MBTL1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250332155-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LTD (IN) | 2025-10-30 | — | — | US | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2006023750-A2 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | MERCK SHARP & DOHME LTD. (GB) | 2006-01-19 | — | — | US | disclosed |
| WO-2005121094-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTI-HIV-AGENTS | PFIZER LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| WO-2004041826-A1 | IMIDAZOPYRAZINONES AND IMIDAZOTRIAZINONES DERIVATES AS GABA-A RECEPTOR ANXIOLYTIC | MERCK SHARP & DOHME LIMITED (GB) | 2004-05-21 | — | — | WO | disclosed |
| EP-0157399-B1 | 4-(5H-Dibenzo[a,d]cyclohepten-5-yl) piperidine compounds | MERCK & CO. INC. (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4758577-A | 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds for treating cardiovascular disorders | MERCK & CO., INC. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0157399-A2 | 4-(5H-Dibenzo[a,d]cyclohepten-5-yl) piperidine compounds | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | disclosed |
| US-4507294-A | TREATMENT OF PEPTIC ULCERS | SCHERING CORP. (US) | 1985-03-26 | — | — | US | disclosed |
| US-4483858-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1984-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332155-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | NUDT1 3657/4885L3MBTL1 4628/4885DYRK1A 2564/4885 |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC9 | NUDT1 4680/4885L3MBTL1 2432/4885DYRK1A 1941/4885 |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, CTTN | NUDT1 4719/4885L3MBTL1 3673/4885DYRK1A 1646/4885 |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | GABRA3, GABRA2, GABRA1 | NUDT1 4363/4885L3MBTL1 3794/4885DYRK1A 911/4885 |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | HDAC6, HDAC1, HDAC8 | NUDT1 4185/4885L3MBTL1 570/4885DYRK1A 1811/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | NUDT1 83/4885L3MBTL1 3687/4885DYRK1A 3651/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | NUDT1 1845/4885L3MBTL1 3942/4885DYRK1A 583/4885 |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | AXL, WEE1, FLT3 | NUDT1 3447/4885L3MBTL1 4739/4885DYRK1A 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.